Relative Quantitation of Human Polymorphonuclear Leukocyte Cell Membrane GPEtn Lipids

Similar documents
SUPPLEMENTARY DATA. Materials and Methods

LC-Based Lipidomics Analysis on QTRAP Instruments

Comprehensive Lipid Profiling of Human Liver Tissue Extracts of Non-Alcoholic Fatty Liver Disease

SWATH Acquisition Enables the Ultra-Fast and Accurate Determination of Novel Synthetic Opioids

Identification & Confirmation of Structurally Related Degradation Products of Simvastatin

The use of mass spectrometry in lipidomics. Outlines

LC/MS/MS SOLUTIONS FOR LIPIDOMICS. Biomarker and Omics Solutions FOR DISCOVERY AND TARGETED LIPIDOMICS

Identification of Ginsenosides Using the SCIEX X500R QTOF System

Core E Analysis of Neutral Lipids from Human Plasma June 4, 2010 Thomas J. Leiker and Robert M. Barkley

Comprehensive Forensic Toxicology Screening in Serum using On-Line SPE LC-MS/MS

Fast and simultaneous analysis of ethanol metabolites and barbiturates using the QTRAP 4500 LC-MS/MS system

Supporting information

Quantification of PtdInsP 3 molecular species in cells and tissues by mass spectrometry

Key Advantages of Comprehensive Cannabis Analysis

Mass Spectrometry based metabolomics

High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines

Rapid, Simple Impurity Characterization with the Xevo TQ Mass Spectrometer

Rapid Lipid Profiling of Serum by Reverse Phase UPLC-Tandem Quadrupole MS

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

O O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions

Glycerolipid Analysis. LC/MS/MS Analytical Services

Supplementary Information. Effects of Perfluorooctanoic Acid on Metabolic Profiles in Brain and Liver of Mouse by a

Enrichment of Phospholipids from Biological Matrices with Zirconium Oxide-Modified Silica Sorbents

Advancing your Forensic Toxicology Analyses; Adopting the Latest in Mass Spectrometry Innovations

A Definitive Lipidomics Workflow for Human Plasma Utilizing Off-line Enrichment and Class Specific Separation of Phospholipids

Sequence Identification And Spatial Distribution of Rat Brain Tryptic Peptides Using MALDI Mass Spectrometric Imaging

Shuguang Li, Jason Anspach, Sky Countryman, and Erica Pike Phenomenex, Inc., 411 Madrid Ave., Torrance, CA USA PO _W

Determination of 6-Chloropicolinic Acid (6-CPA) in Crops by Liquid Chromatography with Tandem Mass Spectrometry Detection. EPL-BAS Method No.

Achieve Broad Lipid Quantitation using a High-Throughput Targeted Lipidomics Method

Phospholipid characterization by a TQ-MS data based identification scheme

LC/MS Method for Comprehensive Analysis of Plasma Lipids

Designer Cannabinoids

Applying a Novel Glycan Tagging Reagent, RapiFluor-MS, and an Integrated UPLC-FLR/QTof MS System for Low Abundant N-Glycan Analysis

Simple Method (IS-MRM) to Monitor Lysophospholipids and Phospholipids During LC-MS Method Development via In-Source CID

Robust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS

Automated Purification and Analytical Reinjection of a Small Molecule Drug, Probenecid, on a Gilson LC/MS Dual Function System

The detergent-solubilized and gel filtration purified rhodopsin was partitioned against

Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research

Obtaining Answers to Biological Questions Sample Prep to Data Analysis. Jeremiah D. Tipton, Ph.D. SCIEX Advanced Workflow Specialist in OMICS

methods Electrospray mass spectrometry of human hair wax esters Mark Fitzgerald and Robert C. Murphy 1

Ultra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification

Characterization of an Unknown Compound Using the LTQ Orbitrap

Determination of Amantadine Residues in Chicken by LCMS-8040

Comprehensive Two-Dimensional HPLC and Informative Data Processing for Pharmaceuticals and Lipids

Essential Lipidomics Experiments using the LTQ Orbitrap Hybrid Mass Spectrometer

Profiling the Distribution of N-Glycosylation in Therapeutic Antibodies using the QTRAP 6500 System

Extraction of a Comprehensive Steroid Panel from Human Serum Using ISOLUTE. SLE+ Prior to LC/MS-MS Analysis

Identification of Steroids in Water by Ion Trap LC/MS/MS Application

Improving Selectivity in Quantitative Analysis Using MS 3 on a Hybrid Quadrupole-Linear Ion Trap Mass Spectrometer

Overview. Introduction. Experimental. Cliquid Software for Routine LC/MS/MS Analysis

Modernizing the Forensic Lab with LC-MS/MS Technology

Vitamin D3 and related compounds by ESI and APCI

Screening and Speciation of Raw and Processed Meat Products

Accurate Quantification of Lipid Species by Electrospray Ionization Mass Spectrometry Meets a Key Challenge in Lipidomics

PTM Discovery Method for Automated Identification and Sequencing of Phosphopeptides Using the Q TRAP LC/MS/MS System

Analysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ

application Natural Food Colorants Analysis of Natural Food Colorants by Electrospray and Atmospheric Pressure Chemical Ionization LC/MS

Matrix Factor Determination with the Waters Regulated Bioanalysis System Solution

Extraction of Multiple Mycotoxins From Nuts Using ISOLUTE Myco prior to LC-MS/MS Analysis

Extraction of Aflatoxin M1 From Infant Formula Using ISOLUTE Myco SPE Columns prior to LC-MS/MS Analysis

SPE-LC-MS/MS Method for the Determination of Nicotine, Cotinine, and Trans-3-hydroxycotinine in Urine

Rapid Analysis of Water-Soluble Vitamins in Infant Formula by Standard-Addition

Agilent 6470 Triple Quadrupole LC/MS System and EMR-Lipid. The Combination for Confident Pesticide Quantitation. Christoph Mueller

Fast, Robust and Reliable Method for the Identification and Quantitation of Sildenafil Residue in Honey using LC-MS/MS

Tandem mass spectrometry analysis of prostaglandins and isoprostanes

Fast Separation of Triacylglycerols in Oils using UltraPerformance Convergence Chromatography (UPC 2 )

New Solvent Grade Targeted for Trace Analysis by UHPLC-MS

Application Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer

Detection, Confirmation, and Quantification of Chloramphenicol in Honey, Shrimp and Chicken Using the Agilent 6410 LC/MS Triple Quadrupole

Supporting Information

Determination of red blood cell fatty acid profiles in clinical research

A RAPID AND SENSITIVE ANALYSIS METHOD OF SUDAN RED I, II, III & IV IN TOMATO SAUCE USING ULTRA PERFORMANCE LC MS/MS

Dienes Derivatization MaxSpec Kit

Chapter 6 IDENTIFICATION AND CHARACTERIZATION OF FLAVONOIDS BY HPLC AND LC-MS/MS ANALYSIS

Detection of Low Level of Chloramphenicol in Milk and Honey with MIP SPE and LC-MS-MS

Determination of Selected Illegal Drugs and its Important Metabolites in Waste Water by Large Volume Direct Injection HPLC-MS/MS

Determination of Aflatoxins in Food by LC/MS/MS. Application. Authors. Abstract. Experimental. Introduction. Food Safety

Designer Fentanyls Drugs that kill and how to detect them. Cyclopropylfentanyl

SelexION Technology for Lipid Analysis: Pushing the Boundaries of Lipidomics

Application Note. Author. Abstract. Introduction. Food Safety

SCIEX Vitamin D 200M Assay for the Topaz System

Mass-Based Purification of Natural Product Impurities Using an Agilent 1260 Infinity II Preparative LC/MSD System

Analytical Method for 2, 4, 5-T (Targeted to Agricultural, Animal and Fishery Products)

Neosolaniol. [Methods listed in the Feed Analysis Standards]

Use of Derivatization for LC- MS/MS Analysis in the Clinical Lab

LC-MS/MS Method for the Determination of Tenofovir from Plasma

SEPARATION OF BRANCHED PFOS ISOMERS BY UPLC WITH MS/MS DETECTION

Application Note. Abstract. Authors. Pharmaceutical

Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid

Measuring Lipid Composition LC-MS/MS

Quantification of lovastatin in human plasma by LC/ESI/MS/MS using the Agilent 6410 Triple Quadrupole LC/MS system

Characterization and direct quantitation of cerebroside

Supporting Information

Extraction of Multiple Mycotoxins From Grain Using ISOLUTE Myco prior to LC-MS/MS Analysis

LC/MS/MS Separation of Cholesterol and Related Sterols in Plasma on an Agilent InfinityLab Poroshell 120 EC C18 Column

SUPPORTING INFORMATION FOR: CONCENTRATIONS OF POLYBROMINATED DIPHENYL ETHERS, HEXABROMOCYCLODODECANES AND TETRABROMOBISPHENOL-A IN BREAST MILK FROM

Rapid Screening and Quantitation of Postharvest Fungicides on Citrus Fruits Using AxION DSA/TOF and Flexar SQ MS

Determination of N-Nitrososarcosine (NSAR) in tobacco

Sample Preparation is Key

Transcription:

Relative Quantitation of Human Polymorphonuclear Leukocyte Cell Membrane GPEtn Lipids Using the QTRAP System with mtraq Reagents Karin A. Zemski-Berry 1, John M. Hevko 2, and Robert C. Murphy 1 1 Department of Pharmacology, University of Colorado Health Sciences Center, USA, 2 AB SCIEX, USA Phospholipids are well known as the building blocks of cellular membranes, but their role in biochemistry is only partially understood. In addition to forming the physical boundary of cells and compartmentalizing the subcellular components, phospholipids are involved in many key regulatory functions within mammalian cells. For example, membrane phospholipids are the source of arachidonic acid (AA), which is the precursor of lipid mediators such as leukotrienes and prostaglandins. Given the importance of phospholipids, there is great interest in monitoring these species and observing the changes that occur as a result of stimulation of a cell to initiate a biological response. A powerful method to identify and quantitate these phospholipids present in a cell extract is electrospray tandem mass spectrometry (ESI/MS/MS). MS/MS spectra possess unique product ions and neutral losses in both the positive and negative ion mode that are indicative of the polar head group and fatty acyl substituents 1, respectively. While the use of mass spectrometry and the stable isotope dilution strategy has been a powerful qualitative and quantitative approach to address changes in biomolecules, there are few sources for stable isotope phospholipid internal standards for such studies. Figure 1. 3-Dimensional Model of Glycerophosphoethanolamine (GPEtn) Lipid. Previously, a method was developed using isobaric itraq reagents and direct infusion MS 3 IDA to monitor the changes in Glycerophosphoethanolamine (GPEtn) lipids after calcium ionophore stimulation and subsequent cleavage of arachidonic acid from phospholipids 2. This method was successful in providing some insight into the changes of arachidonate containing GPEtn lipids of stimulated samples compared to control samples. Useful quantitative information was obtained in the positive ion mode through the itraq reagent reporter ions formed during CID, however these are not present in negative ion mode. The use of direct infusion MS3 was absolutely necessary in the analysis of these changes, but the ability to observe changes in the detail necessary for our studies was hindered due to the inability to couple this method with liquid chromatography and to obtain useful negative ion mode data. The mtraq reagents (non-isobaric amine labeling reagents, similar to the itraq reagents) were developed to enable LC- MRM (Multiple Reaction Monitoring) analysis of aminecontaining biomolecules. Analysis of mtraq reagent labeled GPEtn lipids can be achieved by LC-MRM strategies in both the positive or negative ion mode, providing significant improvement in quantitation over the previous itraq reagent strategy. The non-isobaric nature of these reagents (4 Da mass difference) eliminates the need for MS 3 analysis of GPEtn lipids. The ability to use MRM transitions in the negative ion mode for mtraq reagent labeled GPEtn lipids allows for more specific transitions to be selected, providing better specificity for the fatty acids esterfied to the glycerol backbone. This method allowed one to monitor changes specifically in arachidonate containing GPEtn lipids. p 1

Methods and Materials Samples: Human polymorphonuclear leukocyte experiments with A23187 and acrolein: Human polymorphonuclear leukocytes (neutrophils) were obtained from the whole blood of volunteers using the Percoll gradient centrifugation technique as previously described 3. The neutrophils (20x10 6 cells) were spun down and resuspended in HBSS at a concentration of 10x10 6 cells/ml. The cell suspension (1 ml) was then aliquotted into separate tubes for the control and A23187 treated experiments. CaCl2 (final concentration 2 mm) and MgCl2 (final concentration 500 µm) were added to the control and A23187 treated samples. A23187 is a compound that elevates calcium levels and thereby activates cpla2, which releases AA from membrane phospholipids. A23187 was added to the A23187 treated sample for a final concentration of 2 µm. The control and A23187 treated samples were allowed to incubate at 37 C for 10 min and the reaction was stopped by the addition of one volume of ice-cold methanol. The cell membranes were pelleted by centrifugation and saved for mass spectrometric analysis. Sample Preparation: Lipids were extracted from the cell pellets of the control and A23187 treated samples by addition of chloroform-methanol-water according to the method of Bligh and Dyer4. Additionally, 14:0a/14:0-GPEtn (2 g) was added as an internal standard to each sample. The phospholipid extract was labeled with mtraq reagent using the same procedure as outlined for itraq reagent labeling of GPEtn lipids2. The control GPEtn lipids were labeled with mtraq reagent 4 and the A23187 GPEtn lipids were labeled with mtraq reagent 0. Each sample was separately introduced onto the SPE column. Chromatography: A C18 5 m Phenomenex Gemini (2.0 x 150 mm) column (Phenomenex, Torrance, CA) was used. The HPLC was operated at a flow rate of 200 L/min with a mobile phase of methanol-acetonitrile-water 60:20:20 (v/v/v) with 1 mm ammonium acetate (solvent A) and 1 mm methanolic ammonium acetate (solvent B). The initial mobile phase was 75% solvent B which was held for 2 min. A gradient was started at 2 min from 75% solvent B to 100% solvent B in 5 min, followed by isocratic elution at 100% solvent B for 23 min. Mass Spectrometry: All of the mass spectrometry experiments were performed on a QTRAP system in both the positive and negative ion mode. MRM triggered IDA on a QTRAP system was used initially to determine the mtraq reagent labeled GPEtn species present in the human neutrophil in positive ion mode. Specific MRM methods in both positive and negative ion mode were developed for mtraq reagent labeled GPEtn species. Figure 2. Positive Ion Mode MS/MS Characterization of 18:0p/20:4- GPEtn. Enhanced product ion spectra of the [M+H]+ of 1-O-1'-(Z)- octadecenyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0p/20:4-GPEtn) labeled at the primary amine group with (a) mtraq reagent 0 and (b) mtraq reagent 4 with a collision energy of 30V. The origins of the ions that resulted from fragmentation by collisional activation are indicated in the structures of these molecules. Positive Ion MRM Analysis of mtraq Reagent Labeled GPEtn Lipids GPEtn lipids from neutrophils were labeled with either 0 or 4 versions of the mtraq reagent. The +EPI of mtraq reagent 0 labeled 18:0p/20:4-GPEtn revealed an mtraq reagent specific ion at m/z 282.2 (Figure 2a), whereas the mtraq reagent specific ion for mtraq reagent 4 labeled 18:0p/20:4- GPEtn was at m/z 286.2 (Figure 2b). The fragment ions at m/z 282 and 286 result from cleavage at the phosphate-glycerol bond with the site of protonation being the mtraq reagent modified polar headgroup of the GPEtn lipid. p 2

An MRM method was built using 34 MRM mtraq reagent transitions for all 16 GPEtn lipids that were identified from previous itraq reagent experiments1 as well as the 14:0a/14:0- GPEtn internal standard (Figure 3). The MRM transitions (Q1 Q3) of mtraq reagent labeled GPEtn molecular species corresponded to Q1 m/z 282 for mtraq reagent 0 labeled and Q1 m/z 286 for mtraq reagent 4 labeled, where Q1 corresponds to the [M+H]+ ions for each molecular species. MRM triggered IDA was used to verify the structure of GPEtn lipids identified from the MRM survey scan. Figure 3. Positive Ion LC-MRM Data of GPEtn Lipids From Human Neutrophils. Control GPEtn lipids were labeled with mtraq reagent 4 and detected by MRM transitions Q1 m/z 286 where Q1 corresponds to the [M+H]+ ions for each molecular species. GPEtn lipids from A23187 treated neutrophils were labeled with mtraq reagent 0 and monitored using the MRM transitions of Q1 m/z 282. A total of 34 MRM transitions were monitored, 17 from each sample including the internal standard. For some mtraq reagent labeled GPEtn lipids, this data revealed the many isobaric compounds under these conditions, highlighting the complexity of GPEtn lipids in neutrophils. The extracted MRM of 894 282 (Figure 4a) and 918 282 (Figure 4b) are two examples that highlight the presence of multiple isobaric compounds of some of the GPEtn species in the human neutrophils, which demonstrates the complexity of these samples. MRM transition m/z 894 282 could represent mtraq reagent labeled 18:0p/20:3-GPEtn, 18:0e/20:4-GPEtn, 20:1p/18:2-GPEtn, or 16:0e/22:4-GPEtn, which are isobaric species that contain different fatty acids. In addition, the MRM transition m/z 918 282 could represent mtraq reagent labeled 18:0p/22:5-GPEtn, 20:1p/20:4, or 18:1p/22:4-GPEtn, which are isobaric species that contain different fatty acids. All of these isobaric species which contain different fatty acids cannot be differentiated by their +EPI spectrum due to no characteristic fatty acid fragment ions in the positive ion mode. Figure 4. MRM Triggered IDA Data Highlights Complexity of GPEtn Lipids. The MRM transitions (Q1 Q3) of (a) m/z 894 282 and (b) m/z 918 282 were extracted from same data shown in Figure 3. Note that there are multiple chromatographic peaks for both MRM transitions, which indicates the presence of isobaric species in the.control GPEtn lipids, where Q1 corresponds to the [M+H]+ ions for each molecular species. p 3

Negative Ion MRM Analysis of mtraq Reagent Labeled GPEtn Lipids GPEtn lipids have characteristic negative ion MS/MS spectra, containing rich structural information about the fatty acids esterified to the glycerol backbone. For this reason, the negative ion LC/MRM approach for the GPEtn lipids previously identified by itraq reagent labeling 1 was investigated. The negative MS/MS spectrum (-EPI) of mtraq reagent 0 labeled 18:0p/20:4-GPEtn (Figure 5a) and the mtraq reagent 4 labeled 18:0p/20:4-GPEtn (Figure 5b) both contain a major fragment ion at m/z 303 which corresponds to arachidonic acid. Figure 5. Negative Ion Mode MS/MS Characterization of 18:0p/20:4- GPEtn. Enhanced product ion spectra of the [M-H]- of 1-O-1'-(Z)- octadecenyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0p/20:4-GPEtn) labeled at the primary amine group with (a) mtraq reagent 0 and (b) mtraq reagent 4 at a collision energy of 35V. The origins of the ions that resulted from collisional activation are indicated in the structures of these molecules. The EPI spectra obtained in negative ion mode contain specific fatty acid fragment ions but do not contain mtraq reagent and/or itraq reagent specific fragment ions. The corresponding negative MRM method provided specificity for each mtraq reagent labeled GPEtn lipid, which could not be achieved in the positive ion mode. In addition to GPEtn lipids positively identified in the original itraq reagent work1, several other GPEtn lipids thought to be important were added to the final MRM method of 64 MRM transitions for all 32 GPEtn mtraq reagent labeled lipids (Figure 6). The MRM transitions of mtraq reagent labeled GPEtn molecular species corresponded to predicted m/z Q1 Q3, where Q1 corresponds to the [M-H]- ion for each molecular species and Q3 corresponds to the fatty acids esterifed to the glycerol backbone. Figure 6. Negative ion LC-MRM of GPEtn lipids. GPEtn lipids from control neutrophils (labeled with mtraq reagent 4) and A23187 treated neutrophils (labeled with mtraq reagent 0) were monitored by negative mode LC-MRM. Thirty two glycerophosphoethanolamine lipids present in the human neutrophils, including the internal standard, were monitored. The MRM transitions used for mtraq reagent labeled GPEtn molecular species corresponded to predicted Q1 Q3, where Q1 corresponds to the [M-H]- ion for each molecular species and Q3 corresponds to the fatty acids esterifed to the glycerol backbone. p 4

The specificity to distinguish between different isobaric GPEtn lipids in negative mode as opposed to positive mode is shown in Figure 7. In positive ion mode, the MRM transition m/z 918 282 was monitored and showed three different chromatographic peaks at 16.5, 17.8, and 18.2 min (Figure 7a). These peaks are isobaric and could not be further distinguished in positive ion mode by MRM or MS/MS analysis. In negative ion mode, these isobaric peaks could be differentiated by monitoring the MRM transitions m/z 916 303 (20:1p/20:4), 916 329 (18:0p/22:5- GPEtn or 18:1e/22:5-GPEtn), and 916 331 (18:1p/22:4-GPEtn) (Figure 7b). The negative ion mode MRM data reveals that the first chromatographic peak at 16.5 min in Figure 7a is the 18:1p/22:4-GPEtn lipid (Figure 7b, gray). The two chromatographic peaks at 17.1 and 17.8 min (red and green, Figure 7b), which corresponded to 20:1p/20:4 and 18:0p/22:5- GPEtn, contribute to the second chromatographic peak in Figure 7a that is centered at 17.8 min. Finally, the last chromatographic peak at 18.2 min was identified as 18:1e/22:5-GPEtn from the negative ion mode data (second green peak, Figure 7b). Figure 7. Improved Specificity in Negative Ion Mode. The MRM transition of (a) m/z 918fi282 was extracted from Figure 3. Note the multiple chromatographic peaks for this particular [M+H]+. The MRM transitions of (b) m/z 916fi303 (red), 916fi329 (green), and 916fi331 (gray) were extracted from the same data shown in Figure 6. This negative MRM data reveals the identity of the isobaric GPEtn lipids in the positive MRM data. This specificity in the negative ion mode allowed for the observation of changes of specific phospholipids after stimulus. For example, 20:1p/20:4-GPEtn decreases much more (red to green, Figure 8) than 18:1p/22:4-GPEtn after A23187 stimulus (blue to pink, Figure 8), which indicates that arachidonatecontaining GPEtn lipids are more affected by A23187 stimulus. Figure 8. Relative Quantitation of Specific GPEtn Lipids in Neutrophils. The MRM transitions of m/z 916fi303 (green) and 920fi303 (red) from 0 and 4 mtraq reagent labeled 20:1p/20:4- GPEtn were extracted from the same data shown in Figure 6. It is apparent that this particular arachidonic acid containing phospholipid decreases upon A23187 treatment (green) compared to the control (red). Additionally, the MRM transitions of m/z 916fi331 (pink) and 920fi331 (blue) from 0 and 4 mtraq reagent labeled 18:1p/22:4-GPEtn extracted from the same dataset show that this particular nonarachidonic acid containing phospholipid does not change upon A23187 treatment (pink) compared to the control (blue). Using this negative ion MRM method, eight arachidonate containing mtraq reagent labeled GPEtn species were monitored and all showed decreases after treatment with A23187 as compared to the 24 non-arachidonate containing GPEtn species monitored. This negative ion MRM workflow using mtraq reagent to label GPEtn lipids will allow for the monitoring of changes of specific phospholipids after biological stimulation which has not been achieved previously. p 5

Conclusions The non-isobaric mtraq reagents provide an excellent solution for the quantitative monitoring of Glycerophosphoethanolamine (GPEtn) lipids in human neutrophils This example illustrates a pairwise comparison of treated vs. control samples, however this workflow is extensible to multiple sample comparisons through use of a mtraq reagent labeled Reference Internal Standard strategy, where the labeled control sample is added to multiple treated lipid samples in parallel Ability to use both positive and negative ion polarities with the mtraq reagent labeling strategy provides more qualitative and quantitative information References 1. M. Pulfer, R. C. Murphy, Mass Spectrom. Rev. 22 (2003) 332-364 2. K.A. Zemski Berry, R.C. Murphy, J.Lipid Res. 46 (2005) 1038-1046 3. C. Haslett, L.A. Guthrie, M. Kopaniak, R.B. Johnston, Jr., P.M.Henson, Am. J. Pathol. 119 (1985) 101-110 4. E.G. Bligh, W.J. Dyer, Can. J. Biochem. Physiol. 37 (1959) 911-917 For Research Use Only. Not for use in diagnostic procedures. 2010 AB SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX is being used under license. Publication number: 0923210-01 p 6